_bono-parp-qu-tan-caro-est2024-gus-lucioni-preview-1.jpg "Bono PARP: ¿Qué Tan CARO Está?(2024) Gus Lucioni from parp Video Screenshot Preview 1")
Gallery_bono-parp-qu-tan-caro-est2024-gus-lucioni-preview-3.jpg "Bono PARP: ¿Qué Tan CARO Está?(2024) Gus Lucioni from parp Video Screenshot Preview 3")
Gallery_bono-parp-qu-tan-caro-est2024-gus-lucioni-preview-hqdefault.jpg "Bono PARP: ¿Qué Tan CARO Está?(2024) Gus Lucioni from parp Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 11 minutes 27 seconds
👁 View: 2.8K times
Play Audio:👁 View: 2.8K times
Description:
Gustavo Lucioni
Gustavo Lucioni
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_parp-inhibitors-for-maintenance-therapy-in-ovarian-cancer.webp "Cleveland Clinic")
_gynecologic-cancer-education-parp-inhibitor-therapy.webp "Mayo Clinic")
_mechanism-of-action-of-parp-inhibitors-and-targeting-dna-damage-response-ddr.webp "Understand the mechanism of action of PARP inhibitors and targeting DNA Damage Response (DDR) in this short video")
⏲ 3 min 10 sec ✓ 25-Jul-2019
_personalizing-advanced-ovarian-cancer-treatment-with-parp-inhibitors-and-novel-approaches.webp "PeerView Oncology")
⏲ 57 minutes 11 seconds 👁 2.5K
_susana-m-campos-md-mph-on-the-role-of-parp-inhibitors-in-the-treatment-landscape-of-ovarian-cancer.webp "Susana M. Campos, MD, MPH, of Dana-Farber Cancer Institute, discusses recent changes to the NCCN Ovarian Cancer Guidelines and the implications for treatment going forward.")
⏲ 1 min 37 sec ✓ 26-Apr-2018
_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat.webp "UCLA Health")
⏲ 34 minutes 17 seconds 👁 4.6K
_parp-inhibitors-revolutionising-cancer-treatment.webp "astrazeneca")
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.webp "Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.")
_parp-inhibitors-for-maintenance-therapy-in-ovarian-cancer.jpg)
_gynecologic-cancer-education-parp-inhibitor-therapy.jpg)
_mechanism-of-action-of-parp-inhibitors-and-targeting-dna-damage-response-ddr.jpg)
_personalizing-advanced-ovarian-cancer-treatment-with-parp-inhibitors-and-novel-approaches.jpg)
_susana-m-campos-md-mph-on-the-role-of-parp-inhibitors-in-the-treatment-landscape-of-ovarian-cancer.jpg)
_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat.jpg)
_parp-inhibitors-revolutionising-cancer-treatment.jpg)
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.jpg)
![[+]](/images/menu.gif){kind=small}